SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany
6 references·0 citing·29 second hop
The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany (2009)The impact of reference pricing on switch…The use of logit and probit models in strategic management research: Critical issues (2007)The use of logit and probit m…Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures? (2005)Regulation of pharmaceutical …Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers (2003)Clinical and economic consequ…Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme Inhibitors (2002)Outcomes of Reference Pricing…Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. (2002)Impact of reference-based pri…Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization (2001)Effect of a Three-Tier Prescr…Econometric Models and Economic Forecasts (1990)Discrete Choice Methods with Simulation (2001)Discrete choice methods with simulation (2004)Necessity as the mother of ‘green’ inventions: Institutional pressures and environmental innovations (2012)Corporate Social Responsibility Reporting in China: Symbol or Substance? (2013)Thinking about U : Theorizing and testing U ‐ and inverted U ‐shaped relationships in strategy research (2015)Payment Restrictions for Prescription Drugs under Medicaid (1987)METHODS FOR ANALYZING HEALTH CARE UTILIZATION AND COSTS (1999)Adverse Events Associated With Prescription Drug Cost-Sharing Among Poor and Elderly Persons (2001)Proposal of the Physicians' Working Group for Single-Payer National Health Insurance (2003)Benefits And Risks Of Increasing Restrictions On Access To Costly Drugs In Medicaid (2004)The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use (2013)Effects of Medicaid Drug-Payment Limits on Admission to Hospitals and Nursing Homes (1991)Effect of Increased Cost-Sharing on Oral Hypoglycemic Use in Five Managed Care Organizations (2005)Impact of a generic substitution reform on patients’ and society's expenditure for pharmaceuticals (2006)Effects of Reference Pricing in Pharmaceutical Markets (2010)Global Budgeting in Germany: Lessons for the United States (1994)The German experience in reference pricing (1998)The Importance of the Physician in the Generic versus Trade-Name Prescription Decision (1998)Having Your Cake and Eating It (2008)Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status (2017)The Effect of Drug Co-Payments on Utilization and Cost of Pharmaceuticals in a Health Maintenance Organization (1990)Estimating the Burden of Disease (1997)Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 Inhibitors (2004)What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries (2008)Pharmaceutical policies: effects of cap and co-payment on rational use of medicines (2015)A therapeutic substitution policy for proton pump inhibitors: Clinical and economic consequences (2006)Pharmaceutical Pricing and Reimbursement Policies in Canada (2009)The impact of reference-pricing systems in Europe: a literature review and case studies (2011)
this work references cited by second hop

References

  • 2007The use of logit and probit models in strategic management research: Critical issues1,516 cited
  • 2002Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme Inhibitors178 cited
  • 2001Effect of a Three-Tier Prescription Copay on Pharmaceutical and Other Medical Utilization161 cited
  • 2002Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.102 cited
  • 2003Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers59 cited
  • 2005Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures?51 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work